Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 21, 2016
The power and potential of digitized and linked data require careful stewardship. For example, integrating routine data and HIV registers could generate efficiencies and potentially improve the delivery of health care services, but linking these systems may also put individuals’ privacy at gre...
Blog Post
October 04, 2016
Routine operational data on government programs lack sexiness, and are generally not trendy with Data Revolutionaries. But unlike censuses and household surveys, routine administrative data are readily available at low cost, cover key populations and service providers, and are generally at the ...
Blog Post
September 26, 2016
Zika’s rapid spread has focused media attention on how poorly prepared both rich and less rich countries are for infectious disease outbreaks. And while it seems that we are still flailing, in fact, the international community has been trying to do better for a while. Perhaps the most sign...
Blog Post
September 01, 2016
In his previous role as head of water, sanitation, and hygiene (WASH) at the Bill & Melinda Gates Foundation, Louis Boorstin worked to co-invest with the World Bank in at-scale programs that would be rigorously evaluated. The unique result: lives saved in the real world, measured rigorously...
Blog Post
May 15, 2013
This is a joint post with Kate McQueston.
Mobile applications – or ‘apps’ – seem to be the latest craze in mobile technology for global health programming. The proliferation of these apps is converging around a growing interests in open (and big) data, so you don&rsquo...
Blog Post
November 10, 2012
There was bad news in research published yesterday in the New England Journal of Medicine about the effectiveness of what had seemed to be the best prospect for a malaria vaccine, known by the unsexy name of 'RTS,S'.
The study of the phase III trials finds that in babies (aged 6-12 weeks) the vac...